DermTech, Inc.

DermTech, Inc. (Nasdaq: DMTK) is a dermatology-focused molecular diagnostics company that entered the public markets through a SPAC business combination in 2019, with the transaction reflected in an 8-K filing dated August 7, 2019. The company develops non-invasive genomic testing technology for skin conditions, most notably its Smart Sticker platform designed to aid in the detection of melanoma without traditional surgical biopsy. Operating within the healthcare and precision diagnostics sector, DermTech positioned itself as an innovator in the dermatology diagnostics space at the time of its public debut. For full filing history, deal terms, sponsor details, and post-merger trading data on DMTK, sign up for complete access at SpacDesk.